Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Treon

Showing results (151-160 of 323) with videos related to

Pageof 33
Sort By:
Clinical Lymphoma & Myeloma|April 14, 2009
Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemiaBryan T Ciccarelli, Guang Yang, Evdoxia Hatjiharissi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemiaSteven P Treon, Mark Hansen, Andrew R Branagan, et al.
Epigenomics|December 28, 2020
Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibitionStephan J Matissek, Weiguo Han, Mona Karbalivand, et al.
Blood|September 26, 2008
Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemiaSophia Adamia, Amanda A Reichert, Hemalatha Kuppusamy, et al.
Seminars in Oncology|April 30, 2003
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaRoger G Owen, Steven P Treon, Ayad Al-Katib, et al.
British Journal of Haematology|May 14, 2011
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemiaSteven P Treon, Guang Yang, Christine Hanzis, et al.
British Journal of Haematology|April 17, 2004
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myelomaNoopur Raje, Teru Hideshima, Faith E Davies, et al.
Blood|July 10, 2013
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemiaGuang Yang, Yangsheng Zhou, Xia Liu, et al.
Haematologica|August 12, 2017
CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinibJosephine M Vos, Nickolas Tsakmaklis, Christopher J Patterson, et al.
Blood|December 15, 2018
Bruton tyrosine kinase degradation as a therapeutic strategy for cancerDennis Dobrovolsky, Eric S Wang, Sara Morrow, et al.
Pageof 33

Showing results (151-160 of 323) with videos related to

Sort By:
Pageof 33
Clinical Lymphoma & Myeloma|April 14, 2009
Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemiaBryan T Ciccarelli, Guang Yang, Evdoxia Hatjiharissi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemiaSteven P Treon, Mark Hansen, Andrew R Branagan, et al.
Epigenomics|December 28, 2020
Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibitionStephan J Matissek, Weiguo Han, Mona Karbalivand, et al.
Blood|September 26, 2008
Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemiaSophia Adamia, Amanda A Reichert, Hemalatha Kuppusamy, et al.
Seminars in Oncology|April 30, 2003
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaRoger G Owen, Steven P Treon, Ayad Al-Katib, et al.
British Journal of Haematology|May 14, 2011
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemiaSteven P Treon, Guang Yang, Christine Hanzis, et al.
British Journal of Haematology|April 17, 2004
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myelomaNoopur Raje, Teru Hideshima, Faith E Davies, et al.
Blood|July 10, 2013
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemiaGuang Yang, Yangsheng Zhou, Xia Liu, et al.
Haematologica|August 12, 2017
CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinibJosephine M Vos, Nickolas Tsakmaklis, Christopher J Patterson, et al.
Blood|December 15, 2018
Bruton tyrosine kinase degradation as a therapeutic strategy for cancerDennis Dobrovolsky, Eric S Wang, Sara Morrow, et al.
Pageof 33